Skip to main content
ArticleOPEN ACCESS

AMD3100/Plerixafor overcomes immune inhibition by the CXCL12–KRT19 coating on pancreatic and colorectal cancer cells

British Journal of Cancer
DOI: 10.1038/s41416-021-01315-y
13Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.
Get full text

Abstract

A recent Phase 1 clinical study of the immunological effects of inhibiting the chemokine receptor, CXCR4, in patients with pancreatic ductal adenocarcinoma or colorectal cancer suggests that stimulation of CXCR4 on immune cells suppresses the intratumoural immune reaction. Here, we discuss how CXCR4 mediates this response, and how cancer cells elicit it.

Cite

CITATION STYLE

APA

Fearon, D. T., & Janowitz, T. (2021, July 20). AMD3100/Plerixafor overcomes immune inhibition by the CXCL12–KRT19 coating on pancreatic and colorectal cancer cells. British Journal of Cancer. Springer Nature. https://doi.org/10.1038/s41416-021-01315-y

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free